ADVERTISEMENT

Indoco Remedies Q3 Results Review - Margin Weakness To Persist In Q4; Downgrade To Reduce: Yes Securities

Disappointment driven by weak domestic growth as sales rise 4% YoY, below IPM growth rate for the quarter

<div class="paragraphs"><p>Indoco Remedies Ltd.'s R&amp;D facility. (Source: Company website)</p></div>
Indoco Remedies Ltd.'s R&D facility. (Source: Company website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit